Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Mar;15(1):11-2.
doi: 10.1007/s40268-015-0086-8.

'Similar to' is not 'identical with', and 'identical with' is not 'the same as'

Wolfgang H Jost  1
Affiliations
Comment

'Similar to' is not 'identical with', and 'identical with' is not 'the same as'

Wolfgang H Jost. Drugs R D. 2015 Mar.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Truong D, Jost WH. Therapeutical use of botulinum toxin. Parkinsonism Rel Disord. 2006;12:331–355. doi: 10.1016/j.parkreldis.2006.06.002. - DOI - PubMed
    1. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15. doi:10.1007/s40268-014-0077-1. - PMC - PubMed
    1. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120:275–290. doi: 10.1007/s00702-012-0893-9. - DOI - PMC - PubMed
    1. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in an LD50 assay. J Neural Transm. 2012;119:13–15. doi: 10.1007/s00702-011-0719-1. - DOI - PubMed
    1. Brown M, Nicholson G, Ardila MC, et al. Comparative evaluation of the potency and antigenicity of two distinct BoNT/A-derived formulations. J Neural Transm. 2013;120:291–298. doi: 10.1007/s00702-012-0854-3. - DOI - PubMed

MeSH terms

Substances